Izana Bioscience: against COVID-19 Company
Entity: Izana Life Sciences
Category: Treatment Development
Description: Izana Bioscience is a biopharmaceutical company focused on bringing innovative science to market.
Project: IZN-101
Summary: Izana Bioscience is developing a fully human monoclonal antibody therapy, namilumab (IZN-101), targeting granulocyte-macrophage colony stimulating factor (GM-CSF), which is in development for rheumatoid arthritis and ankylosing spondylitis. IZN-101 is under investigation for its use against the ongoing COVID-19 pandemic, to halt the rapid deterioration of patients with acute respiratory distress. Izana said April 6 it initiated a two-center compassionate use study of namilumab to treat patients with rapidly worsening COVID-19 before ICU admission and prior to ventilation. The study is being conducted in cooperation with the Humanitas research group, led by Prof. Carlo Selmi, MD, PhD, head of the Rheumatology and Clinical Immunology Unit at Humanitas Research Hospital and Associate Professor of Internal Medicine at Humanitas University.
Category: Treatment Development
Description: Izana Bioscience is a biopharmaceutical company focused on bringing innovative science to market.
Project: IZN-101
Summary: Izana Bioscience is developing a fully human monoclonal antibody therapy, namilumab (IZN-101), targeting granulocyte-macrophage colony stimulating factor (GM-CSF), which is in development for rheumatoid arthritis and ankylosing spondylitis. IZN-101 is under investigation for its use against the ongoing COVID-19 pandemic, to halt the rapid deterioration of patients with acute respiratory distress. Izana said April 6 it initiated a two-center compassionate use study of namilumab to treat patients with rapidly worsening COVID-19 before ICU admission and prior to ventilation. The study is being conducted in cooperation with the Humanitas research group, led by Prof. Carlo Selmi, MD, PhD, head of the Rheumatology and Clinical Immunology Unit at Humanitas Research Hospital and Associate Professor of Internal Medicine at Humanitas University.
Technology:
Treatment Development
Headquarters:
United Kingdom
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership